Medical Practice Valuation: 2025 Guide

If you’re a healthcare business owner, valuation is no longer an abstract number; it can be the difference between exiting at a life-changing figure or a middling outcome.

In today’s market, most professional buyers (private equity platforms, health systems, and strategic consolidators) price practices on adjusted EBITDA and apply a multiple dependent on many factors, including specialty and location. While you can’t change those items, multiples are sensitive to five forces you can influence: quality of earnings, scale, ancillaries, payer mix, and credible growth. Interest rates and credit availability set the backdrop, but your preparation can determine whether you land in the bottom quartile of outcomes or the top.

The best multiples are achieved through buyer competition, so when you are ready, it is important to market your practice through a structured process.

This article translates current market benchmarks into practical, table-driven takeaways. Treat the ranges as guideposts, not promises; your value will track the quality of earnings you can prove during diligence and buyer/seller dynamics unique to each transaction.

What you’ll learn in this article:

Jump to Read:

• Valuation Basics: Maximizing EBITDA and Multiples
• Valuation Approaches in Healthcare M&A
• Typical EBITDA Multiples by Healthcare Vertical (U.S., 2024–2025)
• The Platform Premium by Size Band
• Payer Mix and Ancillaries: Levers That Move Your Multiple
• What Pushes You to The High or Low End By Specialty
• Sector Spotlights (What the Numbers Mean in Practice)
• How Buyers Underwrite (and Where You Can Influence Outcomes)
• Readiness Roadmap

EV ≈ Adjusted EBITDA × Sector/Scale Multiple

Physician Practices: Multi-Specialty & Medical Groups

Independent groups most often transact in the mid- to high-single-digit EBITDA arena. Crossing into $5M+ EBITDA with ancillary revenue and recruiting momentum often shifts the buyer pool from “local add-on” to “platform-ready,” where multiples can move toward ~10×–12×. Pure physician-to-physician sales in unconsolidated fields can clear at a lower level, sometimes on revenue or asset value, when EBITDA is thin.

Value Drivers:

• Documented growth path (de-novos, extender hiring, service-line adds)
• Durable referral base and payer diversity
• Clean add-backs and month-over-month KPI stability

Valuation Challenges:

• Single-key producer nearing retirement with no succession plan
• Flat or declining visit trends going into marketing
• Unvetted add-backs that won’t survive diligence

Dental Support Organization (DSO)

DSOs remain active buyers. Healthy multi-location groups commonly land ~7×–11× with pedo/ortho and Oral and Maxillofacial Surgery (OMS) at the upper end. Single-site practices with an EBITDA of under $1 million typically trade at a lower valuation unless they are specialty “gems.”

Value Drivers:

• Multi-office density, provider leverage beyond a single star, robust hygiene recall
• A concrete clinic expansion plan (hours, chairs, de novos) with historical proof of execution

Valuation Challenges:

• Heavy Medicaid exposure without a path to mix improvement
• Flat production and high attrition masked by marketing specials

Behavioral Health

Ranges are wide by sub-sector. Small clinics often trade ~3×–8×; mid-size regional operators with in-network contracts and a continuum of care typically see ~5×–10×; the largest, fastest-growing autism/eating-disorder platforms can still achieve low teens in 2025.

Value Drivers:

• In-network commercial mix
• Multi-level programs
• Strong outcomes
• Accreditation
• Multi-state infrastructure and a repeatable new-site playbook

Valuation Challenges:

• OON dependence
• Staffing churn
• Prior compliance issues

Ophthalmology

The market continues to prize ASC-enabled eye care. Small non-ASC practices cluster ~5×–7×; add an ASC and mid-size groups rise to ~7×–9×; multi-ASC, high-MD count platforms can reach ~10× or above. Retina-only practices can achieve additional competition from specialty buyers.

Value Drivers:

• ASC margin stability
• Diversified revenue (clinic, surgery, optical)
• Younger physicians in the mix

Valuation Challenges:

• Medicare rate sensitivity without offsetting commercial mix (though higher Medicare payor mix expected within specialty)
• Senior-heavy partner group without a recruiting pipeline

Women’s Health (OB/GYN)

Sizable, diversified groups commonly achieve high-single-digit to low-double-digit multiples, especially with imaging, surgery, fertility, or menopause programs already in place (or with a credible build-out plan).

Valuation Drivers:

• Comprehensive service stack, predictable prenatal volumes, and post-acute programs
• Strong governance and call-coverage models that mitigate burnout risk

Valuation Challenges:

• High med-mal cost trend, heavy OB burden with narrow call pool

Medical Spas & Aesthetics

Aesthetics is cash-pay and brand-driven. Single-site clinics often clear ~3×–6×; regional chains ~5×–8×; scaled, multi-state brands may achieve ~7×–12×, with rare outliers above on forward growth.

Valuation Drivers:

• Membership/subscription revenue, high repeat rates, multi-market brand equity
• A demonstrated de-novo replication playbook and device ROI discipline

Valuation challenges:

• Owner-operator key-person risk, purely transactional revenue, device vendor overhang

Putting It Together: Maximize EBITDA, Expand The Multiple, Protect Value

Valuation is the product of what you earn, how you earn it, and who is bidding. This article shows where your specialty tends to price; the levers and checklists show how to move up the curve. With thoughtful normalization, a crisp growth plan, and a competitive process targeting the right acquirers in your niche, it’s realistic to capture top-quartile outcomes, even in a cautious credit environment.

If you’d like more information, reach out to us here.